[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-progressive-multiple-sclerosis":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":29,"states":30},"Primary progressive multiple sclerosis",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07667322","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis",[11],"Phase 1","RECRUITING","2026-08-03T01:02:27.992967Z","2026-07-05T20:59:06.676422Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07609719","A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy",[19],"Phase 4","2026-08-03T02:41:09.847474Z","2026-05-29T15:36:40.228777Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT07477639","Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.290600Z",[],[]]